KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Prepaid Assets (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Prepaid Assets for 6 consecutive years, with $28.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets fell 3.5% year-over-year to $28.6 million, compared with a TTM value of $28.6 million through Dec 2025, down 3.5%, and an annual FY2025 reading of $28.6 million, down 3.5% over the prior year.
  • Prepaid Assets was $28.6 million for Q4 2025 at Recursion Pharmaceuticals, down from $37.3 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $43.7 million in Q2 2024 and bottomed at $2.5 million in Q1 2025.
  • Average Prepaid Assets over 5 years is $21.3 million, with a median of $17.0 million recorded in 2022.
  • The sharpest move saw Prepaid Assets soared 488.78% in 2022, then crashed 94.05% in 2025.
  • Year by year, Prepaid Assets stood at $7.5 million in 2021, then skyrocketed by 111.19% to $15.9 million in 2022, then soared by 153.62% to $40.2 million in 2023, then decreased by 26.45% to $29.6 million in 2024, then dropped by 3.5% to $28.6 million in 2025.
  • Business Quant data shows Prepaid Assets for RXRX at $28.6 million in Q4 2025, $37.3 million in Q2 2025, and $2.5 million in Q1 2025.